Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of EBITDA data on record, last reported at -$5.1 million in Q3 2025.

  • For Q3 2025, EBITDA rose 83.1% year-over-year to -$5.1 million; the TTM value through Sep 2025 reached $82.4 million, up 216.09%, while the annual FY2024 figure was -$63.7 million, 17.62% down from the prior year.
  • EBITDA reached -$5.1 million in Q3 2025 per ABEO's latest filing, down from $108.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $108.9 million in Q2 2025 and bottomed at -$46.7 million in Q4 2021.
  • Average EBITDA over 5 years is -$8.1 million, with a median of -$12.1 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 450.47% in 2023, then soared 1359.97% in 2025.
  • A 5-year view of EBITDA shows it stood at -$46.7 million in 2021, then surged by 93.56% to -$3.0 million in 2022, then crashed by 450.47% to -$16.6 million in 2023, then skyrocketed by 44.43% to -$9.2 million in 2024, then surged by 44.51% to -$5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$5.1 million in Q3 2025, $108.9 million in Q2 2025, and -$12.1 million in Q1 2025.